Regulus Therapeutics (RGLS) has 1 split in our RGLS split history database. The split for RGLS took place on October 04, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of RGLS owned pre-split, the shareholder now owned 1 share. 4 Wall Street analysts have issued ratings and price targets for Regulus Therapeutics in the last 12 months. Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 94.81%. The high price target for RGLS is $2.00 and the low price target for RGLS is $1.00.

Site uses Cookies. This website utilizes cookies and similar technologies for functionality and other purposes including personalization of content. 12/27/2019 · * regulus therapeutics inc (rgls) - plans to recommence mad study of rgls4326 in q1 of 2020. * regulus therapeutics (rgls) - planning to enroll patients with adpkd in additional short-term dosing study in h2 2020 to evaluate rgls4326. Regulus Therapeutics (RGLS) has 1 split in our RGLS split history database. The split for RGLS took place on October 04, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of RGLS owned pre-split, the shareholder now owned 1 share. 4 Wall Street analysts have issued ratings and price targets for Regulus Therapeutics in the last 12 months. Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 94.81%. The high price target for RGLS is $2.00 and the low price target for RGLS is $1.00. Regulus Therapeutics Inc. ( RGLS) is +0.3399 at $2.22, with 236,848 shares traded. PR Newswire Reports: Regulus Announces Successful Restructuring of Sanofi Collaboration. ProShares UltraPro Short QQQ ( SQQQ) is +0.12 at $14.14, with 203,022 shares traded. 11/11/2017 · Find the latest RESHAPE LIFESCIENCES INC (RSLS) stock quote, history, news and other vital information to help you with your stock trading and investing.

The latest Tweets from NickTrades (@Nicktrades20). Equities Trader📈Going Long and Short. Live streaming my trading every morning on YouTube!Join our free 

Site uses Cookies. This website utilizes cookies and similar technologies for functionality and other purposes including personalization of content. 12/27/2019 · * regulus therapeutics inc (rgls) - plans to recommence mad study of rgls4326 in q1 of 2020. * regulus therapeutics (rgls) - planning to enroll patients with adpkd in additional short-term dosing study in h2 2020 to evaluate rgls4326. Regulus Therapeutics (RGLS) has 1 split in our RGLS split history database. The split for RGLS took place on October 04, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of RGLS owned pre-split, the shareholder now owned 1 share. 4 Wall Street analysts have issued ratings and price targets for Regulus Therapeutics in the last 12 months. Their average twelve-month price target is $1.50, suggesting that the stock has a possible upside of 94.81%. The high price target for RGLS is $2.00 and the low price target for RGLS is $1.00. Regulus Therapeutics Inc. ( RGLS) is +0.3399 at $2.22, with 236,848 shares traded. PR Newswire Reports: Regulus Announces Successful Restructuring of Sanofi Collaboration. ProShares UltraPro Short QQQ ( SQQQ) is +0.12 at $14.14, with 203,022 shares traded. 11/11/2017 · Find the latest RESHAPE LIFESCIENCES INC (RSLS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Technical stock forecast for RGLS: Regulus Therapeutics Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate.

Real-time trade and investing ideas on Regulus Therapeutics Inc. RGLS from the largest community of traders and investors. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that Get breaking news and analysis on Regulus Therapeutics Inc. (RGLS) stock, price quote and chart, trading and investing tools. 3/20/2019 · Find the latest Regulus Therapeutics Inc. (RGLS) stock quote, history, news and other vital information to help you with your stock trading and investing. 12/31/2019 · Discover historical prices for RGLS stock on Yahoo Finance. View daily, weekly or monthly format back to when Regulus Therapeutics Inc. stock was issued. Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regulus Therapeutics (NASDAQ:RGLS) Earnings Information. Regulus Therapeutics last posted its earnings data on November 12th, 2019. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.00.

Inpixon, through its subsidiaries, provides big data analytics and location based products and related services worldwide. The company operates in two segments 11/18/2019 · RGLS charts including price, total return, market cap and dividend yield charts. 12/10/2019 · Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. More about Regulus Therapeutics Filing Date T Date Ticker Sector Ind Industry Owner oSt Rel Title T TVal Price L Qty oc Own H r2y r1y r6m r3m r6w r3w r7d r3d f1d f1w f1m f3m f6m f1y What's going on at Regulus Therapeutics (NASDAQ:RGLS)? View breaking news headlines for RGLS stock from trusted media outlets at MarketBeat. Get breaking news and analysis on Advaxis, Inc. (ADXS) stock, price quote and chart, trading and investing tools. Recent Technical Analysis Signals for RGLS - Regulus Therapeutics Inc. RGLS Chart by TradingView Watchlist Portfolio

ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal.

Join Stocktwits for free stock discussions, prices, and market sentiment with millions of investors and traders. Stocktwits is the largest social network for finance. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. TOGETHER WE… believe that microRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease. Regulus Therapeutics has a market capitalization of $18.63 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-48,710,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis. Regulus Therapeutics employs 24 workers across the globe.

12/23/2019 · Regulus Therapeutics Inc. Common Stock (RGLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and 12/27/2019 · RGLS closed up 18.52 percent on Friday, December 27, 2019, on 2.64 times normal volume. The stock rose above its 50 day moving average, improving its RGLS had returned +13.46% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. More Info About Regulus Therapeutics Inc. (RGLS) Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares GuruFocus.com 04:05PM Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire